Download MendeleyOptimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
Buchstaller, H.P., Anlauf, U., Dorsch, D., Kogler, S., Kuhn, D., Lehmann, M., Leuthner, B., Lodholz, S., Musil, D., Radtki, D., Rettig, C., Ritzert, C., Rohdich, F., Schneider, R., Wegener, A., Weigt, S., Wilkinson, K., Esdar, C.(2021) J Med Chem 64: 10371-10392
- PubMed: 34255518
- DOI: https://doi.org/10.1021/acs.jmedchem.1c00800
- Primary Citation of Related Structures:
7OCV - PubMed Abstract:
Constitutive activation of the canonical Wnt signaling pathway, in most cases driven by inactivation of the tumor suppressor APC, is a hallmark of colorectal cancer. Tankyrases are druggable key regulators in these malignancies and are considered as attractive targets for therapeutic interventions, although no inhibitor has been progressed to clinical development yet. We continued our efforts to develop tankyrase inhibitors targeting the nicotinamide pocket with suitable drug-like properties for investigating effects of Wnt pathway inhibition on tumor growth. Herein, the identification of a screening hit series and its optimization through scaffold hopping and SAR exploration is described. The systematic assessment delivered M2912 , a compound with an optimal balance between excellent TNKS potency, exquisite PARP selectivity, and a predicted human PK compatible with once daily oral dosing. Modulation of cellular Wnt pathway activity and significant tumor growth inhibition was demonstrated with this compound in colorectal xenograft models in vivo .
Organizational Affiliation:
Merck KGaA, Global Research & Development, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
